Immucell (ICCC) Shares Outstanding (2010 - 2026)
Immucell's (ICCC) quarterly Shares Outstanding (Entity) came in at $9.1 million in Q4 2025, up 0.7% YoY from $9.0 million in Q4 2024, and little changed on a QoQ basis from $9.1 million in Q3 2025.
Immucell (ICCC) Shares Outstanding (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Shares Outstanding (Entity) data on file, last reported at $9.1 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 0.7% year-over-year to $9.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.1 million (up 0.7% YoY) and the FY2025 annual result came in at $9.1 million, up 0.7% from the prior year.
- Shares Outstanding (Entity) steadied at $9.1 million in Q4 2025, from $9.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $9.1 million in Q2 2025 to a low of $7.3 million in Q1 2021.
- A 5-year average of $8.2 million and a median of $7.8 million in 2021 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) changed 0.0% — and 2025, when it advanced 15.76%.
- Tracing ICCC's Shares Outstanding (Entity) over 5 years: stood at $7.8 million in 2021, then changed by 0.0% to $7.8 million in 2022, then changed by 0.0% to $7.8 million in 2023, then increased by 15.72% to $9.0 million in 2024, then grew by 0.7% to $9.1 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $9.1 million (Q4 2025), $9.1 million (Q3 2025), and $9.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | 9.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.06 Mn |
| Dec 31, 2025 | 9.03 Mn |
| Sep 30, 2025 | 9.05 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Mar 31, 2025 | 8.98 Mn |
| Dec 31, 2024 | 8.17 Mn |
| Sep 30, 2024 | 8.16 Mn |
| Jun 30, 2024 | 7.81 Mn |
| Mar 31, 2024 | 7.75 Mn |
| Dec 31, 2023 | 7.75 Mn |
| Sep 30, 2023 | 7.75 Mn |
| Jun 30, 2023 | 7.75 Mn |
| Mar 31, 2023 | 7.75 Mn |
| Dec 31, 2022 | 7.75 Mn |
| Sep 30, 2022 | 7.75 Mn |
| Jun 30, 2022 | 7.74 Mn |
| Mar 31, 2022 | 7.74 Mn |
| Dec 31, 2021 | 7.59 Mn |
| Sep 30, 2021 | 7.74 Mn |
| Jun 30, 2021 | 7.66 Mn |